首页> 外文期刊>Microbiologia Medica >The Genotype MTBDRplus ver. 2.0 test as a quick indicator of resistance to rifampicin and isoniazid in Mycobacterium tuberculosis strains
【24h】

The Genotype MTBDRplus ver. 2.0 test as a quick indicator of resistance to rifampicin and isoniazid in Mycobacterium tuberculosis strains

机译:基因型MTBDRplus ver。 2.0试验可作为结核分枝杆菌菌株对利福平和异烟肼耐药性的快速指标

获取原文
           

摘要

Tuberculosis is still a global emergency and a major public health problem, in some cases related to the appearance of strains of multi drug resistance (MDR) and extensive drug resistance (XDR) Mycobacterium tuberculosis complex.The correct determination of antibiotic sensitivity profiles is therefore crucial to carry out appropriate treatment aimed to decrease the infectivity of each patient and to reduce mortality. The poor adherence to treatment by the patient or the use of therapies based on a single drug, as a result of incorrect requirements, promote the development of drug-resistance. Have some time on the market of molecular diagnostic tests that allow, quickly and directly from biological sample to search for resistance genes some key drugs of anti-TB therapy (Rifampicin and Isoniazid). One of the tests in question is the Genotype MTBDRplus ver 2.0 which can reveal the presence of genes for resistance to Isoniazid (INH) and Rifampin (RMP).The loci analyzed are those corresponding to the rpoB gene for rifampicin, katG and inhA for isoniazid. Our study is based on the analysis of 83 strains of tubercular Mycobacteria identified and isolated from patients with tuberculosis disease and subjected to the tests sensitivity, searching for mutations and phenotypic susceptibility testing for Rifampicin and Isoniazid.The comparison of the results has shown that the results obtained using the Genotype MTBDRplus ver 2.0 test, were similar to the results obtained by the traditional susceptibility testing.
机译:结核病仍然是全球性的紧急情况,也是一个重大的公共卫生问题,在某些情况下还与多重耐药性(MDR)和广泛耐药性(XDR)结核分枝杆菌复合体的出现有关,因此正确确定抗生素敏感性分布至关重要进行适当的治疗,以降低每个患者的感染力并降低死亡率。由于不正确的要求导致患者对治疗的依从性差或使用基于单一药物的疗法的不良性促进了耐药性的发展。在分子诊断测试市场上有一段时间,可以使您从生物样品中快速直接地寻找抗性基因,这是一些抗结核治疗的关键药物(利福平和异烟肼)。其中一项测试是基因型MTBDRplus 2.0版,该基因型可以揭示存在对异烟肼(INH)和利福平(RMP)的抗性基因。分析的基因座是对应于利福平,ratB基因的利福平,katG和inhA的异烟肼基因。我们的研究基于对从结核病患者中分离出的83株结核分枝杆菌的分析,并对其进行了敏感性测试,寻找利福平和异烟肼的突变以及表型敏感性测试,结果的比较表明结果使用基因型MTBDRplus ver 2.0测试获得的结果与传统药敏测试获得的结果相似。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号